Original Article

You have full text access to this OnlineOpen article

Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fracture: The FLEX Trial

  1. Ann V Schwartz1,*,
  2. Douglas C Bauer2,
  3. Steven R Cummings3,
  4. Jane A Cauley4,
  5. Kristine E Ensrud5,6,
  6. Lisa Palermo1,
  7. Robert B Wallace7,
  8. Marc C Hochberg8,
  9. Adrianne C Feldstein9,
  10. Antonio Lombardi10,
  11. Dennis M Black1

Article first published online: 8 JAN 2010

DOI: 10.1002/jbmr.11

Issue

Journal of Bone and Mineral Research

Journal of Bone and Mineral Research

Volume 25, Issue 5, pages 976–982, May 2010

Additional Information

How to Cite

Schwartz, A. V., Bauer, D. C., Cummings, S. R., Cauley, J. A., Ensrud, K. E., Palermo, L., Wallace, R. B., Hochberg, M. C., Feldstein, A. C., Lombardi, A. and Black, D. M. (2010), Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fracture: The FLEX Trial. J Bone Miner Res, 25: 976–982. doi: 10.1002/jbmr.11

Author Information

  1. 1

    Department of Epidemiology and Biostatistics, University of California–San Francisco, San Francisco, CA, USA

  2. 2

    Department of Medicine, University of California-San Francisco, San Francisco, CA, USA

  3. 3

    Research Institute, California Pacific Medical Center, San Francisco, CA, USA

  4. 4

    Department of Epidemiology, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, Pennsylvania, USA

  5. 5

    Department of Medicine, VA Medical Center, Minneapolis, MN, USA

  6. 6

    Department of Medicine and Epidemiology, University of Minnesota, Minneapolis, MN, USA

  7. 7

    Department of Epidemiology, University of Iowa College of Public Health, Iowa City, IA, USA

  8. 8

    Department of Medicine, University of Maryland Medical Center, Baltimore, MD, USA

  9. 9

    Kaiser Permanente Northwest Center for Health Research, Portland, OR, USA

  10. 10

    Merck & Co. Inc., Rahway, NJ, USA

*185 Berry Street, Suite 5700, San Francisco, CA 94107-1762, USA.

Publication History

  1. Issue published online: 30 APR 2010
  2. Article first published online: 8 JAN 2010
  3. Accepted manuscript online: 8 JAN 2010 12:00AM EST
  4. Manuscript Accepted: 15 DEC 2009
  5. Manuscript Revised: 21 OCT 2009
  6. Manuscript Received: 12 JUN 2009

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (102K)

References

  • 1
    Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures: Fracture Intervention Trial Research Group. Lancet. 1996; 348: 1535–1541.
  • 2
    Liberman UA, Weiss SR, Broll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis: the Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med. 1995; 333: 1437–1443.
  • 3
    Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA. 1998; 280: 2077–2082.
  • 4
    Black DM, Schwartz AV, Ensrud KE, et al. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-Term Extension (FLEX): a randomized trial. JAMA. 2006; 296: 2927–2938.
  • 5
    Delmas PD. Use of alendronate after 5 years of treatment. JAMA. 2007; 297: 1979–1980; author reply: 1980–1981.
  • 6
    Black DM, Reiss TF, Nevitt MC, Cauley J, Karpf D, Cummings SR. Design of the Fracture Intervention Trial. Osteoporos Int. 1993; 3: S29–S39.
  • 7
    Ensrud KE, Barrett-Connor EL, Schwartz A, et al. Randomized Trial of Effect of Alendronate Continuation Versus Discontinuation in Women With Low BMD: Results From the Fracture Intervention Trial Long-Term Extension. J Bone Miner Res. 2004; 19: 1259–1269.
    Direct Link:
  • 8
    Looker AC, Wahner HW, Dunn WL, et al. Updated data on proximal femur bone mineral levels of US adults. Osteoporos Int. 1998; 8: 468–489.
  • 9
    Genant HK, Wu CY, van Kuijk C, Nevitt MC. Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res. 1993; 8: 1137–1148.
    Direct Link:
  • 10
    Black DM, Cummings SR, Stone K, Hudes E, Palermo L, Steiger P. A new approach to defining normal vertebral dimensions. J Bone Miner Res. 1991; 6: 883–892.
    Direct Link:
  • 11
    Eastell R, Cedel SC, Wahner HW, Riggs BL, Melton LJ. Classification of vertebral fractures. J Bone Miner Res. 1991; 6: 207–215.
    Direct Link:
  • 12
    Black DM, Palermo L, Nevitt MC, et al. Comparison of methods for defining prevalent vertebral deformities: the Study of Osteoporotic Fractures. J Bone Miner Res. 1995; 10: 890–902.
    Direct Link:
  • 13
    Ensrud KE, Black DM, Palermo L, et al. Treatment with alendronate prevents fractures in women at highest risk: results from the Fracture Intervention Trial. Arch Intern Med. 1997; 157: 2617–2624.
  • 14
    Cummings SR. A 55-year-old woman with osteopenia. Jama. 2006; 296: 2601–2610.
  • 15
    McClung MR, Geusens P, Miller PD, et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med. 2001; 344: 333–340.
  • 16
    Recker R, Masarachia P, Santora A, et al. Trabecular bone microarchitecture after alendronate treatment of osteoporotic women. Curr Med Res Opin. 2005; 21: 185–194.
View Full Article (HTML) Get PDF (102K)